Independent Drug Safety Oversight Could Lead To Over-Reactions - Enzi
This article was originally published in The Pink Sheet Daily
Executive Summary
Legislation establishing an independent drug safety oversight group for FDA could result in over-reactions to drug safety signals, Senate Health Committee Chairman Michael Enzi (R-Wyo.) told the Food & Drug Law Institute annual conference April 7 in Washington, D.C